TX-CBRE-GROUP,-INC.
27.7.2021 13:32:07 CEST | Business Wire | Press release
CBRE Group, Inc. (NYSE:CBRE) and Turner & Townsend Holdings Limited today announced a definitive agreement whereby CBRE will acquire a 60% ownership interest in, and enter into a strategic partnership with Turner & Townsend, a United Kingdom-based global leader in program, project and cost management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005548/en/
CBRE will acquire a 60% stake for approximately £960 million ($1.3 billion) in cash, with 55% to be paid upon closing. The transaction preserves Turner & Townsend’s existing leadership team, heritage, operational independence and partnership structure, which will hold the remaining 40% ownership interest. The transaction values Turner & Townsend at approximately £1.6 billion ($2.2 billion) and is expected to be immediately accretive to CBRE’s earnings.
Turner & Townsend provides program management, cost consultancy, project management and advisory consulting services for clients in 46 countries. It operates across three business segments: Real Estate (62% of net revenue) – serving investors and occupiers across all property types, including data centers and life-science properties; Infrastructure (31% of net revenue) – notably, transportation, environmental and power generation projects, and Natural Resources (7% of net revenue) – renewable energy, alternative fuels, liquified natural gas and other projects.
For the 12 months ended April 30, 2021, Turner & Townsend’s net revenue totaled approximately £665 million ($923 million) and adjusted EBITDA totaled approximately £124 million ($172 million).
“This is a transformational transaction for our project management business in terms of both breadth and scale of capabilities,” said Bob Sulentic, CBRE’s president and chief executive officer. “We see sizable secular growth opportunities in project management, which are being propelled by rising public and private infrastructure investment and the drive to a low-carbon global economy. Turner & Townsend is by far the best firm to help us realize our ambitions for this business. It is an exceptionally well-run company with a first-rate brand, enviable client base and expertise that complements our capabilities.”
Among the key benefits to Turner & Townsend from the strategic partnership is the opportunity to materially expand its business in the Americas, where CBRE has deep occupier and investor relationships and a leading market presence.
Vincent Clancy, chairman and chief executive officer of Turner & Townsend, said: “The combined partnership of CBRE and Turner & Townsend will create the premier global provider of program, project and cost management from day one. Turner & Townsend will continue to offer independent advice, solutions and program level thinking across the Real Estate, Infrastructure and Natural Resources sectors. Our global network means this applies everywhere in the world – we operate where our clients operate. The combination of unrivalled global footprint, sector expertise, commitment to investment and an incredible team of people will make CBRE and Turner & Townsend the go-to firms in our industry.”
Upon closing the transaction, Mr. Clancy and the existing Turner & Townsend management team will continue to run the company on a day-to-day basis, and all its services will continue to be delivered under the Turner & Townsend brand. Turner & Townsend’s financial results will be consolidated and reported within CBRE’s Global Workplace Solutions (GWS) business segment.
Turner & Townsend will be governed by a new Board of Directors, consisting of three CBRE executives – Mr. Sulentic, Jack Durburg, Global CEO, GWS, and Chandra Dhandapani, Chief Transformation Officer and COO, GWS, and three Turner & Townsend executives – Mr. Clancy, Jeremy Lathom-Sharp, Finance Director, and James Dand, Chief Operating Officer.
The transaction is subject to regulatory approvals and other customary closing conditions. Closing is expected in the fourth quarter of this year.
Morgan Stanley & Co. LLC is acting as financial advisor and Simpson Thacher & Bartlett LLP and Dentons are acting as legal advisors to CBRE. Rothschild & Co is acting as financial advisor and Pinsent Masons LLP as legal advisor to Turner & Townsend.
About CBRE Group, Inc.
CBRE Group, Inc. (NYSE: CBRE), a Fortune 500 and S&P 500 company headquartered in Dallas, is the world’s largest commercial real estate services and investment firm (based on 2020 revenue). The company has more than 100,000 employees serving clients in more than 100 countries. CBRE serves a diverse range of clients with an integrated suite of services, including facilities, transaction and project management; property management; investment management; appraisal and valuation; property leasing; strategic consulting; property sales; mortgage services and development services. Please visit our website at www.cbre.com . We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website at https://ir.cbre.com . Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.
About Turner & Townsend
Founded in 1946, Turner & Townsend, based in the United Kingdom, is an independent professional services company specializing in program management, project management, cost and commercial management and advisory services across the real estate, infrastructure and natural resources sectors. It employs more than 7,000 professionals in 112 offices and serves clients in 46 countries.
Forward-Looking Statements
Certain of the statements in this release regarding the planned acquisition of a 60% ownership interest in Turner & Townsend that do not concern purely historical data are forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are made based on our management’s expectations and beliefs concerning future events affecting us and are subject to uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Accordingly, actual performance, results and events may vary materially from those indicated in forward-looking statements, and you should not rely on forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in forward-looking statements, including, but not limited to, the continued growth of the commercial real estate, infrastructure and natural resources markets globally, and the ability of CBRE and Turner & Townsend to work both cooperatively and independently to capture opportunities in these markets as well as other risks and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements speak only as of the date of this release. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. For additional information concerning factors that may cause actual results to differ from those anticipated in the forward-looking statements and other risks and uncertainties to our business in general, please refer to our SEC filings, including our Form 10-K for the fiscal year ended December 31, 2020 and Form 10-Q for the quarter ended March 31, 2021. Such filings are available publicly and may be obtained from our website at www.cbre.com or upon request from the CBRE Investor Relations Department at investorrelations@cbre.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005548/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
